PTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 3,056 Shares

Posted by Patrick Bannon on Feb 20th, 2026

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) insider Neil Gregory Almstead sold 3,056 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $69.36, for a total value of $211,964.16. Following the completion of the transaction, the insider directly owned 112,140 shares in the company, valued at $7,778,030.40. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Neil Gregory Almstead also recently made the following trade(s):

On Wednesday, February 18th, Neil Gregory Almstead sold 65 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.36, for a total value of $4,508.40.
On Thursday, January 8th, Neil Gregory Almstead sold 59 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.45, for a total transaction of $4,510.55.
On Thursday, January 8th, Neil Gregory Almstead sold 881 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.45, for a total value of $67,352.45.
On Wednesday, January 7th, Neil Gregory Almstead sold 52 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.48, for a total value of $4,028.96.
On Wednesday, January 7th, Neil Gregory Almstead sold 1,026 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.48, for a total value of $79,494.48.
On Tuesday, January 6th, Neil Gregory Almstead sold 54 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.95, for a total value of $4,155.30.
On Tuesday, January 6th, Neil Gregory Almstead sold 1,279 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total value of $98,419.05.
On Monday, November 24th, Neil Gregory Almstead sold 35,572 shares of PTC Therapeutics stock. The shares were sold at an average price of $80.18, for a total transaction of $2,852,162.96.
On Tuesday, November 25th, Neil Gregory Almstead sold 71,928 shares of PTC Therapeutics stock. The shares were sold at an average price of $83.44, for a total transaction of $6,001,672.32.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock traded up $0.76 on Friday, hitting $70.66. 2,532,077 shares of the company’s stock traded hands, compared to its average volume of 1,290,685. The stock has a market capitalization of $5.67 billion, a PE ratio of 8.25 and a beta of 0.48. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50. The firm’s 50-day moving average price is $75.01 and its two-hundred day moving average price is $67.78.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.46). PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The firm had revenue of $164.68 million during the quarter, compared to analyst estimates of $281.45 million. During the same quarter in the prior year, the business earned ($0.85) earnings per share. The business’s revenue was down 22.7% on a year-over-year basis. On average, analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Jefferies Financial Group boosted their target price on PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, October 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of PTC Therapeutics in a research report on Friday. Citigroup boosted their price objective on PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Finally, Barclays upgraded shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $68.00 to $119.00 in a report on Tuesday, January 27th. Ten research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, PTC Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $80.73.

View Our Latest Report on PTC Therapeutics

Trending Headlines about PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: Company reported full‑year 2025 product and royalty revenue that exceeded guidance, strong early commercial uptake of Sephience™ (Q4 Sephience revenue $92M; 2025 Sephience revenue $111M), and $1.95B cash on hand — supports runway for commercialization and R&D. Read More.
Positive Sentiment: Bank of America trimmed its price target from $97 to $93 but kept a “buy” rating, signaling continued analyst conviction and providing potential support for the stock. Read More.
Neutral Sentiment: Full Q4 earnings call transcript and highlights are available for investors parsing management commentary for drivers of the revenue miss (useful to judge one‑time items vs. sustained weakness). Read More.
Negative Sentiment: Q4 results missed badly: EPS of ($1.67) vs. consensus ($0.21) and revenue $164.7M vs. $281.5M expected — revenue fell ~22.7% YoY. That miss is the primary near‑term driver of investor concern. Read More.
Negative Sentiment: Management set FY‑2026 revenue guidance of $700M–$800M versus street consensus near $974M — a sizable downward gap that reduces near‑term upside and likely drove negative sentiment. Read More.
Negative Sentiment: Regulatory uncertainty after PTC withdrew a Translarna NDA has prompted new questions about that program’s prospects and potential revenue contribution. Read More.
Negative Sentiment: Insider selling: VP Mark Elliott Boulding sold ~5,894 shares across Feb. 17–18 (recent Form 4 filings), a modest but visible reduction that some investors view negatively. Read More.

Hedge Funds Weigh In On PTC Therapeutics

A number of large investors have recently modified their holdings of the business. Mcguire Capital Advisors Inc. acquired a new position in PTC Therapeutics during the fourth quarter valued at approximately $397,000. Invesco Ltd. lifted its holdings in shares of PTC Therapeutics by 38.7% during the fourth quarter. Invesco Ltd. now owns 434,285 shares of the biopharmaceutical company’s stock worth $32,988,000 after buying an additional 121,228 shares in the last quarter. Summit Global Investments bought a new stake in PTC Therapeutics in the 4th quarter valued at about $242,000. State of Tennessee Department of Treasury bought a new stake in shares of PTC Therapeutics in the fourth quarter valued at approximately $2,465,000. Finally, Mackenzie Financial Corp grew its holdings in shares of PTC Therapeutics by 17.4% during the 4th quarter. Mackenzie Financial Corp now owns 236,909 shares of the biopharmaceutical company’s stock worth $18,015,000 after purchasing an additional 35,117 shares in the last quarter.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.